London, UK (PRWEB UK) 23 September 2013
Speaking to eyeforpharma, the HTA advisor reiterated the commonly-held belief that the pharmaceutical industry has yet to get to grips with the complex approval and reimbursement landscape across Europe, leading to weak market access approaches and leaving big pharma open to future disappointments.
Sharing his hopes that further talks at the industry summit might help both sides to find a common ground and provide new life-saving treatments to EU residents, Driss was confident that the choppy legislative waters of EU healthcare could be navigated successfully by working in partnership, “although striking progress in Europe in collaborative activities related to HTA has been made - in particular in relation with EUNetHTA's initiatives - key processes are still specific to each Member State. A dedicated presentation by an active member of the key French Committee in charge of HTA evaluation will expose the current HTA process in France. Specific opinions will be illustrated on the basis of real examples. Information will be provided on possible future evolutions.”
“Knowledge of HTA processes are essential to optimize market access once marketing authorization is granted. Considering in particular its epidemiological as well as its economical characteristics, understanding France's specific HTA mechanisms in detail remains crucial.”
Driss Berdaï will be participating in the largest annual HTA & Payers’ Forum alongside representatives from the top European healthcare organisations, including: NHS, NICE, AIFA, EMA, GKV Spitzenverband, DAK, EFPIA and a select number of senior pharmaceutical leaders. The two day forum will be taking place from the 21st-22nd October in Berlin. To see the full list of attendees or for more information on the agenda, visit the official website
For further inquiries, please contact Ben Swanson, Program director at:
Tel: +44 (0) 207 422 4346